Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Chronic lymphocytic leukemia (CLL) features dysregulated B-cell receptor (BCR) signaling promoting proliferation and BCL2-mediated resistance to apoptosis. Ibrutinib irreversibly inhibits Bruton's tyrosine kinase, blocking BCR signaling, whereas venetoclax inhibits BCL2 to induce apoptosis. Preclinical and clinical data support combining these agents, with ibrutinib-induced CLL-cell mobilization potentially enhancing venetoclax sensitivity. Fixed-duration ibrutinib–venetoclax regimens (e.g., GLOW, CAPTIVATE) have shown strong efficacy, but continuous therapy risks resistance and may not account for heterogeneous response kinetics. The FLAIR trial tested whether an MRD-guided duration of ibrutinib–venetoclax—defined as twice the time to undetectable MRD—would improve outcomes compared with standard FCR chemoimmunotherapy in fit, previously untreated CLL patients.

Prior studies demonstrated activity of targeted agents: ibrutinib monotherapy and venetoclax (alone or with anti-CD20) improved outcomes over chlorambucil–obinutuzumab, though OS advantages were limited. The CLARITY study supported ibrutinib–venetoclax efficacy in relapsed/refractory CLL. First-line fixed-duration ibrutinib–venetoclax regimens (GLOW, CAPTIVATE) achieved high MRD negativity after approximately 12 months, but MRD negativity continued to deepen with longer therapy. GAIA-CLL13 showed high MRD-negativity rates with venetoclax–obinutuzumab and with ibrutinib–venetoclax–obinutuzumab, with strong PFS at 3 years. These data provided the rationale for an individualized, MRD-driven duration strategy tested in FLAIR.

Design: Phase 3, multicenter, open-label, parallel-group, randomized, controlled, adaptive platform trial (FLAIR) in the UK. Patients: Previously untreated CLL or small lymphocytic lymphoma deemed fit for FCR. Key exclusions: Richter's transformation, CNS involvement, symptomatic cardiac disease, and >20% del(17p) by FISH. Ethics approvals and informed consent were obtained. Randomization and treatments: Patients were randomized 1:1:1 to FCR, ibrutinib monotherapy, or ibrutinib–venetoclax using minimization with a random element. FCR was given every 28 days for six cycles barring progression/toxicity. Ibrutinib–venetoclax: Ibrutinib 420 mg daily for 8 weeks, then venetoclax ramp-up to 400 mg daily; combination continued up to 6 years unless MRD-based stopping rules, progression, or unacceptable toxicity. MRD-directed stopping: Duration of ibrutinib–venetoclax was twice the time taken to achieve undetectable MRD, based on serial assessments in peripheral blood and bone marrow per a prespecified algorithm. End points: Primary—PFS (randomization to progression or death) comparing MRD-guided ibrutinib–venetoclax vs FCR. Key secondary—OS, MRD rates/dynamics (at 9 months and longitudinally), response rates (iwCLL), safety/toxicity, quality of life, cost-effectiveness, and subgroup analyses by cytogenetics/IGHV. Assessments: Adverse events captured each cycle; MRD assessed in both compartments; cytogenetic hierarchy and PFS by genetic subgroup evaluated. Statistics: Interim PFS analysis triggered at 50% of required events (116 overall) or 69 FCR events; data cutoff May 22, 2023. O'Brien–Fleming alpha-spending (interim boundary P≤0.005; final P≤0.048). Time-to-event via Kaplan–Meier with Hall–Wellner 95% CIs; Cox models adjusted for minimization factors estimated hazard ratios (HRs) with 95% CIs. No multiplicity adjustment across secondary end points; 95% CIs presented without P values.

• Population: 523 randomized (260 ibrutinib–venetoclax; 263 FCR); median age 62 years; 71.3% male; IGHV mutated 33.1%, unmutated 49.9%; 1.3% del(17p) overall. Follow-up median 43.7 months. - Treatment exposure: In FCR, 66.5% completed 6 cycles. In ibrutinib–venetoclax, median cycles received: ibrutinib 27 (range 2–72), venetoclax 25 (1–70). MRD-guided discontinuation: 28.9% stopped by 24 months; 58.0% by 36 months; 78.4% by 60 months. Five patients restarted I+V and remained alive and progression-free. - Progression-free survival: Events—12/260 (4.6%) with I+V vs 75/263 (28.5%) with FCR. 3-year PFS: 97.2% (95% CI, 94.1–98.6) vs 76.8% (95% CI, 70.8–81.7). HR for progression or death: 0.13 (95% CI, 0.07–0.24; P<0.001). Subgroups: IGHV unmutated HR 0.07 (95% CI, 0.02–0.19); IGHV mutated HR 0.54 (95% CI, 0.21–1.38). - Overall survival: Deaths—9 (3.5%) I+V vs 25 (9.5%) FCR. 3-year OS: 98.0% (95% CI, 95.2–99.2) vs 93.0% (95% CI, 88.9–95.6). HR for death: 0.31 (95% CI, 0.15–0.67). Subgroups: IGHV unmutated HR 0.23 (95% CI, 0.06–0.81); IGHV mutated HR 0.61 (95% CI, 0.20–1.82). - MRD outcomes: Bone marrow undetectable MRD at 2 years: 52.4% (95% CI, 45.9–58.9) I+V vs 49.8% (95% CI, 43.2–56.5) FCR; at 5 years: 65.9% (95% CI, 59.5–72.3) vs 49.8%. Peripheral blood undetectable MRD at 1 year: 47.5% (95% CI, 41.2–53.7) I+V vs 66.0% (95% CI, 60.0–72.1) FCR; at 5 years: 92.7% (95% CI, 88.1–97.3) vs 67.9% (95% CI, 61.9–73.9). Undetectable MRD at any time: bone marrow 61.9% vs 40.3% (adjusted OR 2.03; 95% CI, 1.43–2.89); peripheral blood 85.8% vs 60.8% (adjusted OR 3.91; 95% CI, 2.55–6.00). Median time to first undetectable MRD in blood: 12.0 months (95% CI, 11.5–17.3) I+V vs 8.9 months (95% CI, 8.5–9.1) FCR. - Response at 9 months: Overall response 86.5% (95% CI, 81.8–90.4) I+V vs 76.4% (95% CI, 70.8–81.4) FCR (adjusted OR 2.00; 95% CI, 1.26–3.16). Complete response 59.2% (95% CI, 53.0–65.3) vs 49.0% (95% CI, 42.9–55.3) (adjusted OR 1.51; 95% CI, 1.07–2.14). - Safety (within 1 year): Any grade ≥3 AEs common but patterns differed. Grade 3–5 neutropenia: 10.3% I+V vs 47.3% FCR; anemia: 0.8% vs 15.5%; thrombocytopenia: 2.0% vs 10.0%. Febrile neutropenia grade ≥3: 0% I+V vs 5.4% FCR. Fatigue (any grade): 15.5% vs 49.0%; nausea: 17.1% vs 57.7%. Hypertension AEs: in 34 patients (13.5%) I+V vs 4 (1.7%) FCR; atrial fibrillation/arrhythmia AEs in 34 (13.5%) vs 4 (1.7%). Serious AEs: total 194 events in I+V vs 222 in FCR; infections were most common (56 I+V; 45 FCR). Cardiac serious AEs: 10.7% I+V vs 0.4% FCR. G-CSF use: 21.5% I+V vs 56.7% FCR. - Death causes: I+V (n=8 treated patients): infections (3; two COVID-19), sudden unexplained/cardiac (3; two post-treatment), secondary cancers (2). FCR (n=23): infections (10; two COVID-19), secondary cancers (8), sudden unexplained/cardiac (2). - Secondary malignancies: 24 events in 17 I+V patients vs 45 in 34 FCR; MDS/AML: 1 vs 8; Richter’s transformation: 1 vs 4. Incidence of other cancers per 100 patient-years: 2.6 (95% CI, 2.4–2.8) I+V vs 5.4 (95% CI, 5.1–5.7) FCR (HR 0.43; 95% CI, 0.23–0.77).

MRD-guided ibrutinib–venetoclax significantly improved PFS over FCR and showed an OS advantage at 3 years, directly addressing whether an individualized, response-adapted duration outperforms standard chemoimmunotherapy in fit, previously untreated CLL. Benefits were particularly notable in IGHV-unmutated patients, a group with poorer outcomes on standard therapy, while no clear advantage was seen in IGHV-mutated patients at this follow-up. MRD negativity deepened with continued therapy, supporting the rationale for extending combination treatment until durable undetectable disease is achieved rather than using a fixed duration. Safety profiles differed: ibrutinib–venetoclax reduced myelosuppression and febrile neutropenia compared with FCR but increased cardiac events (hypertension, atrial fibrillation/arrhythmias). Secondary myeloid neoplasms and overall secondary cancer incidence were lower with ibrutinib–venetoclax than FCR. These findings support MRD-driven, time-limited targeted therapy to individualize treatment, potentially prolong remissions, and reduce exposure to chemoimmunotherapy toxicities.

In previously untreated, fit CLL patients, MRD-guided ibrutinib–venetoclax with individualized treatment duration (twice the time to undetectable MRD) produced superior progression-free survival and an apparent overall survival benefit versus FCR. The approach yielded high and increasing MRD-negativity rates over time and allowed a substantial proportion of patients to discontinue therapy by 2–3 years. Safety trade-offs included fewer hematologic toxicities and infections than FCR but more cardiac adverse events. Continued follow-up will clarify durability, long-term safety, and subgroup effects. Future work could refine MRD-guided stopping rules, optimize management of cardiac risks, and compare MRD-adapted strategies against other fixed-duration targeted regimens.

• Interim analysis with early stopping for benefit may overestimate effect size, though stringent prespecified O’Brien–Fleming boundaries and proportion of required events were met; ongoing follow-up to final analysis is planned. - Open-label design could introduce assessment bias, although objective end points and centralized procedures mitigate this. - No multiplicity adjustment across secondary outcomes; CIs should not be used for formal hypothesis testing. - Representation of Black patients was low (approximately 2%), potentially limiting generalizability to more diverse populations. - Median follow-up of 43.7 months limits long-term conclusions on durability, late toxicities, and survival, especially in IGHV-mutated subgroups. - Increased cardiac adverse events with ibrutinib–venetoclax warrant caution and may affect applicability to patients with cardiovascular comorbidity.